Feb 26 |
Enlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis
|
Feb 21 |
Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals
|
Feb 7 |
Enlivex announces new patent covering Allocetra cells and their manufacturing method
|
Feb 7 |
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
|
Jan 17 |
Enlivex to initiate Phase 1/2 study of Allocetra for knee osteoarthritis
|
Jan 17 |
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis
|
Dec 20 |
Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis
|
Dec 12 |
Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?
|
Nov 21 |
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer
|